use issued to Okay. night. a detail, that. for all Thank the today's time last do pick up to highlight this taking can to appreciate to release you Great. I we call. But lot press do I time that going you not four the am important join rehash of the want topics. from I
over has continued our with delivering sales reported to that XX% let’s a of visible by increase all, We This sales customers in first day. total just XXXX $XX.X during product review every to a work our team, is the growth. sales results great million So, XXXX.
rotavirus the You half complex XXXX, may enough manufacturer product. of of first through Tri-Shield exceeded Defense of that difficulty the use of of this vaccine and producing recall because supply First the demand sales
manufacturing at lab our successfully and product publicly XXXX. take production opportunity of our work to beginning I would and this development challenge our teams the to command this like together resolve that quality to
half able a As second Tri-Shield through the Defense. approach mass a First distribution result, XXXX, return during to for we market to of selling were
I results second -- to the XXXX of also the important XXXX. to reason, for the that December product by or period think ended the second XXXX sales to $X.X XX, versus half $X.X during the XX% compare For XX, December ended Total million of sales increased XXXX six-month period million it's six-month XXXX. half
stage positive believe this the sales or its are A line growth earnings I than more our line second at is company's development, bottom comment losses. top of and that cash flows important
point page press this, release. to For of I our four
non-GAAP I is the think in the important at it disclosures to release. press look
that certain expenses are taxes. I amount aware in think and like the compensation net of be of non-cash loss, we included and depreciation income stock-based our amortization, should expense
$X.X from Depreciation our page loss press XX, approximately million more December year $XX,XXX for XX, XX, during before EBITDA, the year in during is exceeded approximately four expense which described December detail non-GAAP release, ended increased a December XXXX. taxes financial on night's just ended the measure, alone last the XXXX. year income XXXX to ended
and mother all calf just It talk get off a unnecessary campaign cows vaccination. to a the Defense healthy the deliver needles about start. about our the beyond bit to critical instead to Save newborn for like I marketing is vaccinations. vaccinations, First Thirdly, avoiding to disease
any in our challenges in of product how than response and between is We less face understand cows' and our we believe beef needles how value producing vaccine. producers There's proposition antibiotics most to coming we variable know We increasingly the in calves. less link and are a cows it. to better dairy strong sell
that we has events It with We dose adjust of see expensive a steady equally needed, given batch the this difference does as each and and equal produce. this the way is Plus content so Defense. that for newborn antibiotic to antibody effectively we know The First every first protection protected. variability in require that calf of best -- treatments. not producer is treat for calf is a every
construction To meet Defense growing well increase expanded production to line demand, way. the of manufacturing our for is product First facility capacity under
this approximately upcoming We of our second complete around expect substantially on end from to the annual $XX production million. approximately quarter, $XX schedule to increasing the million work capacity
June Meeting There this will if in tour you're to to Stockholders Portland. an on XX new space be of Annual opportunity able it our to make
pictures We the posting next progress week so. or in construction on in the of some be will our website
initial an with to lastly did manufacturing regards Section of and product the our This the teams FDA queries response of Drug completing about the submission production this recently sets for outstanding facility. to the development will quality our to That information drug first us And Technical plan Re-Tain, detailed and an Substance Substance Drug the inspection phase phase job to second submission from FDA up manufacturing, of products. our include responses manufacturer our later year.
important of we non-cash impact the on I regulatory the of of status sales So, think and expenses production, hit the Re-Tain. expansion, topics; four our status operating capacity our most growth, results,
I filed in the we night. So, press conclusion, last release review to encourage you
on updated Annual please on Also, our XXXX. all the We slide March look a presentation Form details corporate with take deck. about XX, at expect or the Report XX-K file the
on be Investor business and a posted our A very results. believe see summary as I Corporate our our click good today. Presentation. will well it of later website financial and provides objectives, as current on strategy the update Section February Also
to access deck. that slide that -- get For
I the questions to for call which you more yeah, important appreciate to hope save this streamline time your me. hope -- approach I to are
I some said, that lines to will open with So, questions. operator be let's have happy the take for questions. your the
